Injection of 99mTc-ZHER2:41071 (injected mass 1000 μg) enables discrimination between clinically HER2-positive and HER2-negative (scored by using a standard IHC biopsy test) breast cancer after 2 h. Here, ERBB2 is linked to breast carcinoma.